Physician profile
Mark Profetto
NPI 1487852851
$3,331.04
in general payments reported to CMS, 2019-2025
16 companies · $709 in 2025
The $709 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $479 · 2022: $532 · 2023: $994 · 2024: $617 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,177.87 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Abbott Laboratories | $765.18 | 2022-2025 | Proclaim, Eterna, Octrode |
| Boston Scientific Corporation | $511.36 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Abbvie INC. | $235.99 | 2021-2025 | |
| Pfizer INC. | $137.35 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $125.05 | 2021 | |
| Relievant Medsystems, INC. | $120.99 | 2023 | Intracept |
| Collegium Pharmaceutical, INC. | $74.67 | 2022-2024 | Xtampza |
| Biohaven Pharmaceutical Holding Company LTD. | $55.53 | 2022 | |
| Amneal Pharmaceuticals LLC | $43.12 | 2023 | Lyvispah |
| Vertex Pharmaceuticals Incorporated | $20.37 | 2025 | |
| Lilly USA, LLC | $17.31 | 2025 | Zepbound |
| Arbor Pharmaceuticals, INC. | $14.85 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.68 | 2022 | |
| Ibsa Pharma INC. | $13.72 | 2025 | Licart, Flector, Tirosint |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $3.00 | 2023 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Profetto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.